Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553964 · ClinicalTrials.gov registry record · NA
SARS-CoV-2 OTC At Home Test
A NA study, sponsored by 3EO Health.
- Terminated
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT05553964: Clinical Trial NA study, sponsored by 3EO Health.
NCT05553964 is a NA study that was terminated before completion, run by 3EO Health. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05553964, a NA study, was terminated before completion, sponsored by 3EO Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the 3EO Health COVID-19 Test in individuals presenting at a medical facility. In eligible subjects, nasal samples will be collected for use with the 3EO Health COVID-19 Test, which will be compared to the Zymo® rRT-PCR test results obtained via samples specified by the manufacturer (e.g., AN \[anterior nares\] swab) to determine accuracy of the 3EO Health COVID-19 Test in detecting COVID-19 in participants.
Interventions
- DIAGNOSTIC_TEST In Vitro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-10-07 |
| Est. Completion | 2022-11-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553964
The ClinicalTrials.gov registry entry for NCT05553964 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The listed sponsor is 3EO Health, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which In Vitro is the first listed.
NCT05553964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553964 about?
NCT05553964 is a clinical study titled "SARS-CoV-2 OTC At Home Test". The objective of this study is to evaluate the 3EO Health COVID-19 Test in individuals presenting at a medical facility. In eligible subjects, nasal samples will be collected for use with the 3EO Health COVID-19 Test, which will be compared to the Zymo® rRT-PCR test results obtained via samples spec...
What is the current status of trial NCT05553964?
This trial is currently terminated. It is a NA study. The enrollment target is 64 participants. The study started on 2022-10-07. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT05553964?
The interventions under investigation include: In Vitro (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05553964?
This trial is sponsored by 3EO Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.